[
  {
    "ts": "2026-02-11T05:03:17+00:00",
    "headline": "Gilead Sciences Inc (GILD) Q4 2025 Earnings Call Highlights: Strong HIV Sales Drive Growth ...",
    "summary": "Gilead Sciences Inc (GILD) reports robust HIV sales growth and outlines strategic initiatives for 2026, despite facing competitive pressures in cell therapy.",
    "url": "https://finance.yahoo.com/news/gilead-sciences-inc-gild-q4-050317430.html",
    "source": "GuruFocus.com",
    "provider": "yfinance",
    "raw": {
      "id": "d070589a-bdcb-3265-9aa6-e7e12145708f",
      "content": {
        "id": "d070589a-bdcb-3265-9aa6-e7e12145708f",
        "contentType": "STORY",
        "title": "Gilead Sciences Inc (GILD) Q4 2025 Earnings Call Highlights: Strong HIV Sales Drive Growth ...",
        "description": "",
        "summary": "Gilead Sciences Inc (GILD) reports robust HIV sales growth and outlines strategic initiatives for 2026, despite facing competitive pressures in cell therapy.",
        "pubDate": "2026-02-11T05:03:17Z",
        "displayTime": "2026-02-11T05:03:17Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": null,
        "provider": {
          "displayName": "GuruFocus.com",
          "url": "http://www.gurufocus.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/gilead-sciences-inc-gild-q4-050317430.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/gilead-sciences-inc-gild-q4-050317430.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "GILD"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-11T11:29:00+00:00",
    "headline": "These Stocks Are Today’s Movers: Moderna, Robinhood, Cloudflare, Humana, Lyft, Mattel, Beta Technologies, Gilead, and More",
    "summary": "Shares in Moderna tumble after the company says the Food and Drug Administration refuses to review a seasonal flu vaccine application.",
    "url": "https://www.barrons.com/articles/stock-movers-93fe9143?siteid=yhoof2&yptr=yahoo",
    "source": "Barrons.com",
    "provider": "yfinance",
    "raw": {
      "id": "d3c99806-d7e1-34e8-bfb0-e54d087fa7b0",
      "content": {
        "id": "d3c99806-d7e1-34e8-bfb0-e54d087fa7b0",
        "contentType": "STORY",
        "title": "These Stocks Are Today’s Movers: Moderna, Robinhood, Cloudflare, Humana, Lyft, Mattel, Beta Technologies, Gilead, and More",
        "description": "",
        "summary": "Shares in Moderna tumble after the company says the Food and Drug Administration refuses to review a seasonal flu vaccine application.",
        "pubDate": "2026-02-11T11:29:00Z",
        "displayTime": "2026-02-11T11:29:00Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/d3c99806-d7e1-34e8-bfb0-e54d087fa7b0/these-stocks-are-today%E2%80%99s.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/Barrons.com/dfc369dfc75a1f0587c152e0f813ca6b",
          "originalWidth": 1280,
          "originalHeight": 640,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/Uo8UTy_QlezfC1z9StNeHg--~B/aD02NDA7dz0xMjgwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/Barrons.com/dfc369dfc75a1f0587c152e0f813ca6b.cf.webp",
              "width": 1280,
              "height": 640,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/ONvzJWyntskVEcsn7C5YpA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/Barrons.com/dfc369dfc75a1f0587c152e0f813ca6b.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Barrons.com",
          "url": "http://www.barrons.com/"
        },
        "canonicalUrl": {
          "url": "https://www.barrons.com/articles/stock-movers-93fe9143?siteid=yhoof2&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "HOOD"
            },
            {
              "symbol": "BTC-USD"
            },
            {
              "symbol": "MRNA"
            },
            {
              "symbol": "NET"
            },
            {
              "symbol": "HUM"
            },
            {
              "symbol": "LYFT"
            },
            {
              "symbol": "MAT"
            },
            {
              "symbol": "BETA"
            },
            {
              "symbol": "GILD"
            },
            {
              "symbol": "F"
            },
            {
              "symbol": "MSTR"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-11T13:11:15+00:00",
    "headline": "Gilead expects 6% of HIV sales growth in 2026, with $800m Yeztugo target",
    "summary": "Analysts said that Yeztugo’s forecast, which would represent 433% year-over-year growth, is achievable.",
    "url": "https://www.pharmaceutical-technology.com/news/gilead-expects-6-of-hiv-sales-growth-in-2026-with-800m-yeztugo-target/",
    "source": "Pharmaceutical Technology",
    "provider": "yfinance",
    "raw": {
      "id": "7f0786c8-c750-349b-82ef-85bb53367c42",
      "content": {
        "id": "7f0786c8-c750-349b-82ef-85bb53367c42",
        "contentType": "STORY",
        "title": "Gilead expects 6% of HIV sales growth in 2026, with $800m Yeztugo target",
        "description": "",
        "summary": "Analysts said that Yeztugo’s forecast, which would represent 433% year-over-year growth, is achievable.",
        "pubDate": "2026-02-11T13:11:15Z",
        "displayTime": "2026-02-11T13:11:15Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/pharmaceutical_technology_376/1db1c3e83813b81d49aca3c27c4493dc",
          "originalWidth": 1000,
          "originalHeight": 667,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/1Y5V775AIXbWVCye1ufgUQ--~B/aD02Njc7dz0xMDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/pharmaceutical_technology_376/1db1c3e83813b81d49aca3c27c4493dc.cf.webp",
              "width": 1000,
              "height": 667,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/4l7z8DxoVKdOd_no6.6g4A--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/pharmaceutical_technology_376/1db1c3e83813b81d49aca3c27c4493dc.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Pharmaceutical Technology",
          "url": "https://www.globaldata.com/"
        },
        "canonicalUrl": {
          "url": "https://www.pharmaceutical-technology.com/news/gilead-expects-6-of-hiv-sales-growth-in-2026-with-800m-yeztugo-target/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/gilead-expects-6-hiv-sales-131115397.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "GILD"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-11T12:41:00+00:00",
    "headline": "These Stocks Are Today’s Movers: Moderna, Robinhood, Shopify, Kraft Heinz, Cloudflare, Humana, Lyft, Mattel, Beta Tech, and More",
    "summary": "Shares in Moderna tumble after the company says the Food and Drug Administration refuses to review a seasonal flu vaccine application.",
    "url": "https://www.barrons.com/articles/stock-movers-93fe9143?siteid=yhoof2&yptr=yahoo",
    "source": "Barrons.com",
    "provider": "yfinance",
    "raw": {
      "id": "d3c99806-d7e1-34e8-bfb0-e54d087fa7b0",
      "content": {
        "id": "d3c99806-d7e1-34e8-bfb0-e54d087fa7b0",
        "contentType": "STORY",
        "title": "These Stocks Are Today’s Movers: Moderna, Robinhood, Shopify, Kraft Heinz, Cloudflare, Humana, Lyft, Mattel, Beta Tech, and More",
        "description": "",
        "summary": "Shares in Moderna tumble after the company says the Food and Drug Administration refuses to review a seasonal flu vaccine application.",
        "pubDate": "2026-02-11T12:41:00Z",
        "displayTime": "2026-02-11T12:41:00Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/d3c99806-d7e1-34e8-bfb0-e54d087fa7b0/these-stocks-are-today%E2%80%99s.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/Barrons.com/dfc369dfc75a1f0587c152e0f813ca6b",
          "originalWidth": 1280,
          "originalHeight": 640,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/Uo8UTy_QlezfC1z9StNeHg--~B/aD02NDA7dz0xMjgwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/Barrons.com/dfc369dfc75a1f0587c152e0f813ca6b.cf.webp",
              "width": 1280,
              "height": 640,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/ONvzJWyntskVEcsn7C5YpA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/Barrons.com/dfc369dfc75a1f0587c152e0f813ca6b.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Barrons.com",
          "url": "http://www.barrons.com/"
        },
        "canonicalUrl": {
          "url": "https://www.barrons.com/articles/stock-movers-93fe9143?siteid=yhoof2&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "HOOD"
            },
            {
              "symbol": "BETA"
            },
            {
              "symbol": "GILD"
            },
            {
              "symbol": "BTC-USD"
            },
            {
              "symbol": "MRNA"
            },
            {
              "symbol": "SHOP"
            },
            {
              "symbol": "KHC"
            },
            {
              "symbol": "NET"
            },
            {
              "symbol": "HUM"
            },
            {
              "symbol": "LYFT"
            },
            {
              "symbol": "MAT"
            },
            {
              "symbol": "MSTR"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-11T05:31:16+00:00",
    "headline": "GILD Q4 Deep Dive: HIV Prevention and Oncology Advances Drive Mixed Outlook",
    "summary": "Biopharmaceutical company Gilead Sciences (NASDAQ:GILD) reported Q4 CY2025 results beating Wall Street’s revenue expectations, with sales up 4.7% year on year to $7.93 billion. On the other hand, the company’s full-year revenue guidance of $29.8 billion at the midpoint came in 1.2% below analysts’ estimates. Its non-GAAP profit of $1.86 per share was 1.9% above analysts’ consensus estimates.",
    "url": "https://finance.yahoo.com/news/gild-q4-deep-dive-hiv-053116371.html",
    "source": "StockStory",
    "provider": "yfinance",
    "raw": {
      "id": "9978ebad-31d0-335c-9efc-7ab5df86798f",
      "content": {
        "id": "9978ebad-31d0-335c-9efc-7ab5df86798f",
        "contentType": "STORY",
        "title": "GILD Q4 Deep Dive: HIV Prevention and Oncology Advances Drive Mixed Outlook",
        "description": "",
        "summary": "Biopharmaceutical company Gilead Sciences (NASDAQ:GILD) reported Q4 CY2025 results beating Wall Street’s revenue expectations, with sales up 4.7% year on year to $7.93 billion. On the other hand, the company’s full-year revenue guidance of $29.8 billion at the midpoint came in 1.2% below analysts’ estimates. Its non-GAAP profit of $1.86 per share was 1.9% above analysts’ consensus estimates.",
        "pubDate": "2026-02-11T05:31:16Z",
        "displayTime": "2026-02-11T05:31:16Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/stockstory_922/0c2e68ead77a9450e1fb435ed236802c",
          "originalWidth": 1400,
          "originalHeight": 700,
          "caption": "GILD Cover Image",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/7IhZSScYZ4CvnQJJpve_Dg--~B/aD03MDA7dz0xNDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/stockstory_922/0c2e68ead77a9450e1fb435ed236802c.cf.webp",
              "width": 1400,
              "height": 700,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/cv.0mSrHV7hG2Zeh2xc10A--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/stockstory_922/0c2e68ead77a9450e1fb435ed236802c.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "StockStory",
          "url": "https://stockstory.org/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/gild-q4-deep-dive-hiv-053116371.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/gild-q4-deep-dive-hiv-053116371.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "GILD"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-11T15:17:07+00:00",
    "headline": "Gilead Bounds Higher As Analysts Debate The Future Of Its Potential HIV Blockbuster",
    "summary": "Gilead stock reversed higher Wednesday after beating fourth-quarter expectations and issuing strong guidance for Yeztugo.",
    "url": "https://www.investors.com/news/technology/gilead-stock-gilead-sciences-earnings-q4-2025/?src=A00220&yptr=yahoo",
    "source": "Investor's Business Daily",
    "provider": "yfinance",
    "raw": {
      "id": "1b616d78-4f60-39cd-9f96-6ceb8e28749c",
      "content": {
        "id": "1b616d78-4f60-39cd-9f96-6ceb8e28749c",
        "contentType": "STORY",
        "title": "Gilead Bounds Higher As Analysts Debate The Future Of Its Potential HIV Blockbuster",
        "description": "",
        "summary": "Gilead stock reversed higher Wednesday after beating fourth-quarter expectations and issuing strong guidance for Yeztugo.",
        "pubDate": "2026-02-11T15:17:07Z",
        "displayTime": "2026-02-11T15:17:07Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/1b616d78-4f60-39cd-9f96-6ceb8e28749c/gilead-bounds-higher-as.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/ibd.com/c41f2b75ef43110c88cfcb472262eb79",
          "originalWidth": 945,
          "originalHeight": 533,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/shVGxj7bu_u.CpYzNTXRdw--~B/aD01MzM7dz05NDU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/ibd.com/c41f2b75ef43110c88cfcb472262eb79.cf.webp",
              "width": 945,
              "height": 533,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/WU5OlgKO09tNMial_TfFPA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/ibd.com/c41f2b75ef43110c88cfcb472262eb79.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Investor's Business Daily",
          "url": "http://www.investors.com/"
        },
        "canonicalUrl": {
          "url": "https://www.investors.com/news/technology/gilead-stock-gilead-sciences-earnings-q4-2025/?src=A00220&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "GILD"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-11T16:40:51+00:00",
    "headline": "Gilead Sciences Poised for Yeztugo Execution, Pipeline Upside in 2026, Morgan Stanley Says",
    "summary": "Gilead Sciences (GILD) is positioned for moderate upside in 2026, supported by expanding HIV sales,",
    "url": "https://finance.yahoo.com/news/gilead-sciences-poised-yeztugo-execution-164051422.html",
    "source": "MT Newswires",
    "provider": "yfinance",
    "raw": {
      "id": "f82fd174-e81d-33b9-8370-27caa7978c41",
      "content": {
        "id": "f82fd174-e81d-33b9-8370-27caa7978c41",
        "contentType": "STORY",
        "title": "Gilead Sciences Poised for Yeztugo Execution, Pipeline Upside in 2026, Morgan Stanley Says",
        "description": "",
        "summary": "Gilead Sciences (GILD) is positioned for moderate upside in 2026, supported by expanding HIV sales,",
        "pubDate": "2026-02-11T16:40:51Z",
        "displayTime": "2026-02-11T16:40:51Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": null,
        "provider": {
          "displayName": "MT Newswires",
          "url": "https://www.mtnewswires.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/gilead-sciences-poised-yeztugo-execution-164051422.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/gilead-sciences-poised-yeztugo-execution-164051422.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "GILD"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": true,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-11T15:15:00+00:00",
    "headline": "GILD's Q4 Earnings Beat Estimates, HIV and Liver Disease Drugs Power Sales",
    "summary": "Gilead beats Q4 estimates on strong HIV and Liver Disease portfolio performance, but 2026 guidance tempers sentiment despite Yeztugo's solid debut.",
    "url": "https://finance.yahoo.com/news/gilds-q4-earnings-beat-estimates-151500283.html",
    "source": "Zacks",
    "provider": "yfinance",
    "raw": {
      "id": "12e2252d-02b0-3d06-a7d3-684d4e10da7c",
      "content": {
        "id": "12e2252d-02b0-3d06-a7d3-684d4e10da7c",
        "contentType": "STORY",
        "title": "GILD's Q4 Earnings Beat Estimates, HIV and Liver Disease Drugs Power Sales",
        "description": "",
        "summary": "Gilead beats Q4 estimates on strong HIV and Liver Disease portfolio performance, but 2026 guidance tempers sentiment despite Yeztugo's solid debut.",
        "pubDate": "2026-02-11T15:15:00Z",
        "displayTime": "2026-02-11T15:15:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/zacks.com/79b7ecb3a59852f0816e6eb69c31b2fe",
          "originalWidth": 635,
          "originalHeight": 400,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/tEjPL1xniTl4Yv5crLKiVw--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/79b7ecb3a59852f0816e6eb69c31b2fe.cf.webp",
              "width": 635,
              "height": 400,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/3wQ5IrbXljgjZ16xqKRVcQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/79b7ecb3a59852f0816e6eb69c31b2fe.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Zacks",
          "url": "http://www.zacks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/gilds-q4-earnings-beat-estimates-151500283.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/gilds-q4-earnings-beat-estimates-151500283.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "GILD"
            },
            {
              "symbol": "GLAXF"
            },
            {
              "symbol": "GSK"
            },
            {
              "symbol": "RCUS"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-11T22:06:16+00:00",
    "headline": "Yescarta Label Expansion And Dividend Growth Shape Gilead Investment Case",
    "summary": "FDA expands the label for Gilead Sciences' CAR T-cell therapy Yescarta to include relapsed or refractory primary central nervous system lymphoma (PCNSL). The decision removes prior limitations on approval and allows Yescarta to be marketed for this rare, hard to treat cancer. The update marks the first time a CAR T-cell therapy is cleared for use in PCNSL, widening potential access for eligible patients. For investors watching NasdaqGS:GILD, this label expansion aligns with Gilead’s...",
    "url": "https://finance.yahoo.com/news/yescarta-label-expansion-dividend-growth-220616673.html",
    "source": "Simply Wall St.",
    "provider": "yfinance",
    "raw": {
      "id": "8110af0a-33b8-3775-946f-06152e4d2ba6",
      "content": {
        "id": "8110af0a-33b8-3775-946f-06152e4d2ba6",
        "contentType": "STORY",
        "title": "Yescarta Label Expansion And Dividend Growth Shape Gilead Investment Case",
        "description": "",
        "summary": "FDA expands the label for Gilead Sciences' CAR T-cell therapy Yescarta to include relapsed or refractory primary central nervous system lymphoma (PCNSL). The decision removes prior limitations on approval and allows Yescarta to be marketed for this rare, hard to treat cancer. The update marks the first time a CAR T-cell therapy is cleared for use in PCNSL, widening potential access for eligible patients. For investors watching NasdaqGS:GILD, this label expansion aligns with Gilead’s...",
        "pubDate": "2026-02-11T22:06:16Z",
        "displayTime": "2026-02-11T22:06:16Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/simply_wall_st__316/34a971ca153ed4a9b10f7d789bca1b9d",
          "originalWidth": 1194,
          "originalHeight": 432,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/HAEiJmFsYXJTRBPxnneP6w--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/34a971ca153ed4a9b10f7d789bca1b9d.cf.webp",
              "width": 1194,
              "height": 432,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/hXB9F2qU7k4qk3_k1DQd9A--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/34a971ca153ed4a9b10f7d789bca1b9d.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Simply Wall St.",
          "url": "https://simplywall.st/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/yescarta-label-expansion-dividend-growth-220616673.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/yescarta-label-expansion-dividend-growth-220616673.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "GILD"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]